Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma

被引：6

作者：

Wang, Ko-Fan ^{[1
]}

Chang, Cheng-Yu ^{[2
]}

Chang, Shih-Chieh ^{[1
]}

Liu, Yu-Chang ^{[1
]}

Yuan, Mei-Kang ^{[3
]}

Yang, Yuan-Hao ^{[1
]}

机构：

[1] Natl Yang Ming Univ Hosp, Dept Internal Med, Yilan 260, Taiwan

[2] Far Eastern Mem Hosp, Dept Chest Med, New Taipei City, Taiwan

[3] Natl Yang Ming Univ Hosp, Dept Radiol, Yilan 260, Taiwan

来源：

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION | 2013年 / 76卷 / 03期

关键词：

erlotinib; gefitinib; interstitial lung disease; CANCER;

D O I：

10.1016/j.jcma.2013.01.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment for non-small-cell lung cancer with gefitinib and erlotinib is efficacious. However, while many studies have reported on gefitinib-related interstitial lung disease (ILD), less published data are available regarding erlotinib-induced LLD. Here, we report a case of pulmonary adenocarcinoma who developed ILD due to gefitinib initially and erlotinib thereafter. The two episodes of ILD were treated successfully with the discontinuation of the tyrosine kinase inhibitors and high-dose intravenous corticosteroids. Copyright (C) 2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.

引用

页码：173 / 175

页数：3